Mark Milton
Impact in
- Pharmacology top 5%
- Pharmacogenetics and Drug Metabolism
- Oncology top 10%
- Drug Transport and Resistance Mechanisms
- CAR-T cell therapy research
Papers in
- Oncology 16
- CAR-T cell therapy research 7
- Drug Transport and Resistance Mechanisms 7
-
- Peroxisome Proliferator-Activated Receptors 3
- Co-authors
- Patrick Muller (2 shared papers)Christopher Horvath (4 shared papers)Liang‐Shang Gan (2 shared papers)Cindy Q. Xia (2 shared papers)Shenghua Wen (1 shared paper)Sudeep Chandra (1 shared paper)Matthew D. Silva (1 shared paper)Michael D. Henry (1 shared paper)
- Journals
- The AAPS Journal (4 papers)Regulatory Toxicology and Pharmacology (3 papers)Nature reviews. Immunology (2 papers)Biochemical Pharmacology (2 papers)Molecular Therapy — Methods & Clinical Development (2 papers)
- Partner nations
- United StatesSwitzerlandUnited Kingdom
In The Last Decade
Mark Milton
33 papers receiving 1.2k citations
Mark Milton's Hit Papers
Peers
Comparison fields: 5 of 121
- Pharmacology 141
- Oncology 381
- Immunology 212
- Radiology, Nuclear Medicine and Imaging 210
- Molecular Biology 516
Countries citing papers authored by Mark Milton
This map shows the geographic impact of Mark Milton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Milton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Milton more than expected).
Fields of papers citing papers by Mark Milton
This network shows the impact of papers produced by Mark Milton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Milton. The network helps show where Mark Milton may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark Milton, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 36 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | The determination and interpretation of the therapeutic index in drug development Hit paper breakdown → | 2012 | 400 |
| 2 | 2004 | 124 | |
| 3 | 2009 | 88 | |
| 4 | 2007 | 71 | |
| 5 | 1990 | 52 | |
| 6 | 2010 | 43 | |
| 7 | 2008 | 37 | |
| 8 | 2009 | 37 | |
| 9 | 2020 | 35 | |
| 10 | 1988 | 33 | |
| 11 | 2021 | 32 | |
| 12 | 2017 | 31 | |
| 13 | 2022 | 28 | |
| 14 | 2012 | 27 | |
| 15 | 2017 | 25 | |
| 16 | 2009 | 21 | |
| 17 | 2021 | 20 | |
| 18 | 2023 | 18 | |
| 19 | 2015 | 17 | |
| 20 | 2018 | 14 |
About Mark Milton
Mark Milton is a scholar working on Oncology, Molecular Biology, Radiology, Nuclear Medicine and Imaging, Immunology and Pharmacology, having authored 36 papers that have together received 1.2k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (7 papers), CAR-T cell therapy research (7 papers), Drug Transport and Resistance Mechanisms (7 papers), Pharmacogenetics and Drug Metabolism (6 papers), Biosimilars and Bioanalytical Methods (5 papers), Virus-based gene therapy research (4 papers), Peroxisome Proliferator-Activated Receptors (3 papers) and Retinal Diseases and Treatments (3 papers). The work is most often cited by research in Pharmacology (141 citations), Oncology (381 citations), Immunology (212 citations), Radiology, Nuclear Medicine and Imaging (210 citations) and Molecular Biology (516 citations). Mark Milton has collaborated with scholars based in United States, Switzerland and United Kingdom. Frequent co-authors include Patrick Muller, Christopher Horvath, Liang‐Shang Gan, Cindy Q. Xia, Shenghua Wen, Sudeep Chandra, Matthew D. Silva, Michael D. Henry, Peter J. Worland and Jennifer Sims. Their work appears in journals such as The AAPS Journal, Regulatory Toxicology and Pharmacology, Nature reviews. Immunology, Biochemical Pharmacology and Molecular Therapy — Methods & Clinical Development.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.